-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

722.O2.6 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Critical Advances in GVHD Management

Symposia: Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, clinical trials, adult, Translational Research, Thalassemia, Combination therapy, Clinical Research, Hemoglobinopathies, GVHD, pediatric, Diseases, Immune Disorders, Therapies, real-world evidence, Lymphoid Malignancies, registries, young adult , Myeloid Malignancies, Study Population, Human, Transplantation
Sunday, December 11, 2022: 12:00 PM-1:30 PM
208-210 (Ernest N. Morial Convention Center)
Moderators:
Muna Qayed, MD, MSc, ARRAY(0xf7283e0) and Divya Koura, MD, UCSD Moores Cancer Center
Disclosures:
Qayed: Novartis: Honoraria; Vertex: Honoraria. Koura: Cidara: Consultancy.
This session will focus on large studies of the treatment of GVHD, including large real-world observations and randomized studies.
12:00 PM

Leslie S. Kean, MD, PhD1,2,3, Linda J Burns, MD4*, Tzuyung Douglas Kou5*, Christopher Bond6*, Roxanne Kapikian6,7*, Karissa Lozenski6*, Xiao-Ying Tang, MPH4*, Mei-Jie Zhang, PhD4*, Michael T Hemmer8,9*, Sean E Connolly6*, Martin Polinsky6*, Andres Gomez6* and Marcelo C Pasquini, MD, MS4

1Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA
2Dana-Farber Cancer Institute, Boston, MA
3Department of Pediatrics, Harvard Medical School, Boston
4Center for International Blood and Marrow Transplant Research, Milwaukee, WI
5Bristol Myers Squibb (at the time of analysis), Princeton, NJ
6Bristol Myers Squibb, Princeton, NJ
7Cytel Inc., Waltham, MA
8Center for International Blood and Marrow Transplant Research (at the time of analysis), Milwaukee, WI
9Kite Pharma, Santa Monica, CA

12:15 PM

Franco Locatelli, MD1, Hyoung Jin Kang, MD, PhD2, Bénédicte Bruno, MD3*, Virginie Gandemer4*, Fanny Rialland, MD5*, Maura Faraci, MD6*, Yoshiyuki Takahashi, MD, PhD7*, Katsuyoshi Koh, MD8*, Henrique Bittencourt, MD, PhD9, Grace Cleary, MPharm10*, Christine Rosko, BSN11*, Pantelia Roussou, PhD12*, Annie St. Pierre, PhD13*, Anirudh Prahallad, PhD12* and Cristina Díaz-de-Heredia, MD, PhD14*

1IRCCS Ospedale Pediatrico Bambino Gesú, Catholic University of the Sacred Heart, Rome, Italy
2Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children’s Hospital, Seoul, South Korea
3Pediatric Hematology, Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France
4University Hospital of Rennes, Rennes, France
5Service Onco-Hématologie Pédiatrique, Hôpital Mère-Enfant, Nantes University Hospital, Nantes, France
6HSCT Unit, Istituto Giannina Gaslini, Genova, Italy
7Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
8Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan
9Department of Pediatrics, CHU Sainte-Justine, Montreal, QC, Canada
10Novartis Ireland Limited, Dublin, Ireland
11Novartis Pharmaceuticals Corporation, East Hanover, NJ
12Novartis Pharma AG, Basel, Switzerland
13Novartis Pharma AG, Basel, Maryland, Switzerland
14Hospital Universitari Vall d’Hebron, Barcelona, Spain

12:30 PM

Vijaya Raj Bhatt, MBBS, MS1*, Valerie K Shostrom, MS2*, Ayman Saad, MD, MSc3*, Betty K. Hamilton, MD4, Krishna Gundabolu, MBBS5, Lori Maness, MD5, Virender Kumar6*, Ram I Mahato7*, Lynette M. Smith, PhD8*, Taiga Nishihori, MD9 and Stephanie J. Lee, MD, MPH10

1The Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE
2Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE
3James Cancer Center, Ohio State Medical Center, Columbus, OH
4Cleveland Clinic Foundation, Cleveland, OH
5Division of Hematology & Oncology, Department of Internal Medicine, University of Nebraska Medical Center- Fred and Pamela Buffett Cancer Center, Omaha, NE
6University of Nebraska Medical Center, Omaha
7University of Nebraska Medical Center, Omaha, NE
8Department of Biostatistics, University fo Nebraska Medical Center, Omaha, NE
9Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
10Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA

12:45 PM

Liping Dou1*, Yanli Zhao2*, Lei Deng3*, Fang Zhou, PhD3*, Nan Wang1*, Xiangshu Jin1*, Fei Li1*, Liangding Hu1* and Daihong Liu, MD1

1Department of Hematology, Chinese PLA General Hospital, Beijing, China
2Department of Hematopoietic Stem Cell Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China
3Department of Hematology, The 960th Hospital of the People's Liberation Army, Jinan, China

1:00 PM

Rongrong Liu, PhD, MD1*, Meiqing Wu, PhD, MD2*, Qiaochuan Li, PhD, MD3*, Lianjin Liu, MD3*, Chunjie Qin, MD4*, Hong Chen, PhD, MD5*, Lingling Shi, PhD, MD3*, Gaohui Yang, PhD, MD6*, Zeyan Shi, MD3*, Zhongqing Li, PhD, MD3*, Zhenbin Wei, MD7*, Beicai Liu, MD3*, Jing Fan3*, Yinghua Chen8*, Xuemei Zhou3*, Zhongming Zhang, PhD, MD3*, Yongrong Lai, PhD, MD2* and Qifa Liu, MD9

1GuangXi Medical University, Nanning, CHN
2Heamatology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
3The First Affiliated Hospital of Guangxi Medical University, Nanning, China
4Heamatology, Liuzhou Worker’s Hospital, Liuzhou, CHN
5Liuzhou Worker’s Hospital, Liuzhou, China
6The First Affiliated Hospital of Guangxi Medical University, Nanning, CHN
7The First Affiliated Hospital of Guangxi Medical University, Nanning City, CHN
8The First Affiliated Hospital of Guangxi Medical University, Nanning, OH, China
9Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

1:15 PM

Bidesh Kumar Patel, MD1*, Michael J Raabe1*, Vikram Deshpande, MBBS2*, David T Ting, MD1*, Yi-Bin Chen, MD, MS3 and Zachariah Defilipp, MD3

1Massachusetts General Hospital Cancer Center, Boston, MA
2Massachusetts General Hospital, Boston, MA
3Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA

*signifies non-member of ASH